NEW YORK (CBSNewYork) — Malignant melanoma is the deadliest form of skin cancer causing more than 10,000 deaths a year.Once it spreads, fewer than one in ten patients survive, but a new therapy is changing those numbers dramatically and saving countless lives.As CBS2’s Dr. Max Gomez explained melanoma is actually very curable when it’s caught early, but it also spreads very quickly even when it’s a small mole — that’s when it turns deadly. Now, a new class of drugs called immunotherapies is revolutionizing the treatment of advanced melanoma.
PRNewswire/ -- GSK Consumer Healthcare announced today that the U.S. Food and Drug Administration (FDA) has approved FLONASE® Sensimist™ Allergy Relief (fluticasone furoate, 27.5 mcg spray) as an over-the-counter (OTC) treatment for symptoms associated with seasonal and perennial allergies. Previously available by prescription as Veramyst®, FLONASE Sensimist is the latest Rx-to-OTC switch from GSK.
PRNewswire-USNewswire/ -- Research announced today at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo demonstrates that a first-of-its-kind next-generation sequencing test can detect HIV drug resistance mutations that conventional tests fail to identify. This test could play a critical role in helping clinicians to optimize HIV treatment regimens, while also helping public health initiatives to minimize the development of global resistance to antiretroviral drugs.
Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder
RNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that the last patient visits in the Company's reconnect studies, consisting of two pivotal Phase 3 clinical trials of bremelanotide for the treatment of female hypoactive sexual desire disorder (HSDD), have been completed.
CAMBRIDGE & BOSTON, Mass.--(BUSINESS WIRE)--Decibel Therapeutics, a company focused on discovering and developing new medicines to protect, repair and restore hearing, and Samuels & Associates, a commercial real estate developer and owner, today announced that the companies have entered into a lease agreement for Decibel’s new headquarters in Van Ness, located at 1325 Boylston Street in Boston’s Fenway neighborhood. The 32,000 square-feet (SF) of office and laboratory space, which is expected to open in early 2017, will support the company’s continued rapid growth.
SAN ANTONIO--(BUSINESS WIRE)--Inspyr Therapeutics, Inc. (OTCQB: NSPX), a clinical-stage biotechnology company developing novel prodrug therapeutics for the treatment of cancer, announces that Christopher Lowe has been appointed President and Chief Executive Officer, and as a member of the Company’s Board of Directors. Mr. Lowe brings to Inspyr Therapeutics more than 15 years of executive management experience in life sciences as Chief Executive Officer, Chief Financial Officer and Chief Business Officer, and has been an advisor to the Company’s Board of Directors since March 2016.
Evotec Achieves Clinical Development Milestone as Part of Its Multi-Target Alliance with Bayer in Endometriosis
HAMBURG, Germany--(BUSINESS WIRE)--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that it has reached a milestone from Bayer for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.
The American Society for Radiation Oncology (ASTRO) has selected four early career scientists to receive a total of 5,000 in research awards, including one winner of the ASTRO Junior Faculty Career Research Training Award and three recipients of ASTRO Resident/Fellows in Radiation Oncology Research Seed Grants. All winners will be recognized at ASTRO’s 58th Annual Meeting, September 25-28, 2016, at the Boston Convention and Exhibition Center.